相似文献
1
Severe Acute Respiratory Syndrome Coronavirus 2 Human Challenge Trials: Too Risky, Too Soon.严重急性呼吸综合征冠状病毒2人体挑战试验：风险太大，为时过早。
J Infect Dis. 2020 Jul 6;222(3):514-516. doi: 10.1093/infdis/jiaa314.
2
Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines: Setting Expectations Appropriately.严重急性呼吸综合征冠状病毒2疫苗：合理设定预期
Pediatr Infect Dis J. 2020 Jul;39(7):e123-e124. doi: 10.1097/INF.0000000000002741.
3
Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2.接种严重急性呼吸综合征冠状病毒 2 疫苗。
J Pediatric Infect Dis Soc. 2020 Nov 10;9(5):517-518. doi: 10.1093/jpids/piaa093.
4
Challenges in evaluating SARS-CoV-2 vaccines during the COVID-19 pandemic.新冠疫情期间评估新冠病毒疫苗的挑战。
CMAJ. 2020 Aug 24;192(34):E982-E985. doi: 10.1503/cmaj.201237. Epub 2020 Jul 9.
5
A vaccine is not too far for COVID-19.针对新冠病毒的疫苗已为时不远。
J Infect Dev Ctries. 2020 May 31;14(5):450-453. doi: 10.3855/jidc.12744.
6
COVID-19 vaccines: early success and remaining challenges.新冠疫苗：早期成效与尚存挑战
Lancet. 2020 Sep 26;396(10255):868-869. doi: 10.1016/S0140-6736(20)31867-5. Epub 2020 Sep 4.
7
ChAdOx1 nCoV-19 vaccine for SARS-CoV-2.用于预防新型冠状病毒肺炎的腺病毒载体新冠疫苗（ChAdOx1 nCoV-19）
Lancet. 2020 Nov 7;396(10261):1486. doi: 10.1016/S0140-6736(20)32270-4.
8
ChAdOx1 nCoV-19 vaccine for SARS-CoV-2.用于预防新型冠状病毒肺炎的ChAdOx1新型冠状病毒疫苗。
Lancet. 2020 Nov 7;396(10261):1485-1486. doi: 10.1016/S0140-6736(20)32271-6.
9
COVID-19 disrupts vaccine delivery.新冠疫情扰乱了疫苗接种工作。
Lancet Infect Dis. 2020 May;20(5):546. doi: 10.1016/S1473-3099(20)30304-2. Epub 2020 Apr 17.
10
ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 - Authors' reply.用于严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的ChAdOx1新型冠状病毒疫苗——作者回复
Lancet. 2020 Nov 7;396(10261):1486-1487. doi: 10.1016/S0140-6736(20)32267-4.
引用本文的文献
1
Ethical acceptability of human challenge trials: Consultation with the US public and with research personnel.人体挑战试验的伦理可接受性：与美国公众和研究人员的磋商。
PLoS One. 2024 Oct 22;19(10):e0307808. doi: 10.1371/journal.pone.0307808. eCollection 2024.
2
Risk, benefit, and social value in Covid-19 human challenge studies: pandemic decision making in historical context.新冠病毒人体挑战研究中的风险、获益和社会价值：从历史背景看大流行决策
Monash Bioeth Rev. 2022 Dec;40(2):188-213. doi: 10.1007/s40592-022-00156-6. Epub 2022 Jun 15.
3
Public attitudes to a human challenge study with SARS-CoV-2: a mixed-methods study.公众对新型冠状病毒（SARS-CoV-2）人体挑战研究的态度：一项混合方法研究。
Wellcome Open Res. 2022 Feb 10;7:49. doi: 10.12688/wellcomeopenres.17516.1. eCollection 2022.
4
Pandemic vaccine testing: Combining conventional and challenge studies.大流行疫苗测试：常规研究与挑战研究相结合。
Pharmacoepidemiol Drug Saf. 2022 Jun;31(6):710-715. doi: 10.1002/pds.5429. Epub 2022 Mar 31.
5
Human Challenge Studies With Wild-Type Severe Acute Respiratory Sydrome Coronavirus 2 Violate Longstanding Codes of Human Subjects Research.针对野生型严重急性呼吸综合征冠状病毒2的人体激发试验违反了长期以来的人体研究规范。
Open Forum Infect Dis. 2020 Dec 28;8(1):ofaa615. doi: 10.1093/ofid/ofaa615. eCollection 2021 Jan.
6
Testing SARS-CoV-2 vaccine efficacy through deliberate natural viral exposure.通过故意自然病毒暴露来测试 SARS-CoV-2 疫苗的功效。
Clin Microbiol Infect. 2021 Mar;27(3):372-377. doi: 10.1016/j.cmi.2020.12.032. Epub 2021 Jan 6.
7
Is There an Ethical Upper Limit on Risks to Study Participants?研究参与者所面临的风险是否存在伦理上限？
Public Health Ethics. 2020 Nov 3;13(2):143-156. doi: 10.1093/phe/phaa028. eCollection 2020 Jul.
8
Human challenge trials in vaccine development.疫苗研发中的人体挑战试验。
Semin Immunol. 2020 Aug;50:101429. doi: 10.1016/j.smim.2020.101429. Epub 2020 Nov 29.
9
SARS-CoV-2 challenge studies: ethics and risk minimisation.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）挑战研究：伦理与风险最小化
J Med Ethics. 2020 Sep 25;47(12):e79. doi: 10.1136/medethics-2020-106504.
10
Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate.中和抗体与高感染率渔业船舶暴发期间人类免受 SARS-CoV-2 感染相关。
J Clin Microbiol. 2020 Oct 21;58(11). doi: 10.1128/JCM.02107-20.
Zotero 插件